No. Byetta and Bydureon are still prescribed and used today.
The FDA has added information about Byetta side effects to the drug’s label and has advised physicians to use caution in increasing Byetta dosages for patients with kidney problems and to monitor kidney function in patients.
The FDA says in its warning about Byetta and pancreatitis that it has not reached any new conclusions about the safety risks posed by exenatide (Byetta and Bydureon) and other incretin mimetic drugs. The agency is continuing to evaluate all available data to further understand this potential safety issue, it says.